Palifermin biosimilar (Chengdu Zhitian Biotechnology)
冻干重组人角质细胞生长因子（成都芝田生物）
Report date: 2026/05/20 20:02:01
Base Information
Drug NamePalifermin biosimilar (Chengdu Zhitian Biotechnology)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesChengdu Zhitian Biological Engineering Co Ltd
China Registration ClassN/A
Develop Information
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A
Other Information
ATC Code
Related LinksN/A